Get in Touch

AccuraGen to Present at Biotech Showcase™ 2023

Presenting Tuesday, January 10th, 2023 at 9:30am PT
Franciscan-C, Level Ballroom
Key Takeaways
  • AccuraGen’s technology is different. The company utilizes CLAmp sequencing, or “rolling circle” amplification, where copies are only made from the original ctDNA strain found in the patient's blood. Less copies. More accuracy.
  • The company's AccuScan product is more scalable and democratized than competitors, which should result in a highly attractive pitch to hospitals and labs looking to set up on-site MRD testing.
  • MRD monitoring to be a $27 billion market by 2027. AccuraGen has a high performance, democratized solution to compete with Roche, Guardant, and Natera.

San Jose, CA/January 5, 2023 – AccuraGen, today announced that it is presenting at Biotech Showcase™ 2023. This year, registered attendees can view AccuraGen's presentation live, and also access a recorded version beginning November 29th – SIX weeks prior to the actual event. With 24x7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.

George Cardoza, CEO, will be presenting AccuraGen at Biotech Showcase.

Date: Tuesday, January 10th, 2023

Time: 9:30am PT

Track: Franciscan C

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.

“We are delighted that AccuraGen will be joining us in San Francisco and presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”


About AccuraGen

AccuraGen aims to revolutionize cancer management through technology innovation in molecular testing. AccuraGen focuses on the analysis of highly fragmented circulating nucleic acid in blood and has developed proprietary technologies enabling superior performance in the analysis of genomic, epigenetic, and RNA changes.

AccuraGen is headquartered in San Jose, California, USA with CAP-accredited facility in Shanghai, China.

About Biotech Showcase

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 15th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

Key Takeaways
  • AccuraGen’s technology is different. The company utilizes CLAmp sequencing, or “rolling circle” amplification, where copies are only made from the original ctDNA strain found in the patient's blood. Less copies. More accuracy.
  • The company's AccuScan product is more scalable and democratized than competitors, which should result in a highly attractive pitch to hospitals and labs looking to set up on-site MRD testing.
  • MRD monitoring to be a $27 billion market by 2027. AccuraGen has a high performance, democratized solution to compete with Roche, Guardant, and Natera.
Media Gallery
Related Bios
George Cardoza
Chief Executive Officer
View Full Bio>>
Ying Kang
Chairman
View Full Bio>>
Min Cui
Board Member
View Full Bio>>
Dan Zabrowski
Board Member
View Full Bio>>
Kelvin Liu
General Manager of Junson Capital
View Full Bio>>
Wei Xu
Board Member
View Full Bio>>
Contacts
Chelli Miller
chelli@contentcarnivores.com
2199216823